Oncoimmunology

Tumor immunology deals with the natural or therapy-induced recognition of cancers, as well as with the intricate interplay between oncogenesis, inflammation and immunosurveillance. We now create a new, high-profile journal, OncoImmunology, that specifically deals with tumor immunology. Recent progress has allowed for the first clinical demonstration (and FDA approval) of anticancer immunotherapies. There is also an ever growing suspicion that - unexpectedly - many of the currently used chemotherapeutic agents depend in their efficacy on the active contribution of immune effectors. To use a drastic metaphor, oncologists who applied successful chemotherapeutic (or radiotherapeutic) regimens have taken advantage of the immune system's capacity to recognize tumor-specific or tumor-associated antigens and to control cancer (stem) cell growth, without being aware of the invisible helping hands. As a result, immunological biomarkers are becoming ever more important to determine the prognosis of cancers and to predict the efficacy of chemotherapies. There is also a strong rationale in favor of combining conventional anticancer therapies with immunotherapies.

OncoImmunology will accept high-profile submissions in the fundamental, translational and clinical areas of tumor immunology. Submissions dealing with solid or hematological cancers, inflammation, innate and acquired immune responses will be welcome.

肿瘤免疫学涉及自然或治疗诱导的癌症识别，以及癌变、炎症和免疫监视之间错综复杂的相互作用。我们现在创建了一本新的、备受瞩目的期刊《肿瘤免疫学》，专门研究肿瘤免疫学。最近的进展使得抗癌免疫疗法首次获得临床证明（并获得 FDA 批准）。人们也越来越怀疑——出乎意料的是——许多当前使用的化疗药物的疗效取决于免疫效应物的积极作用。打个比方，应用成功的化疗（或放射治疗）方案的肿瘤学家利用了免疫系统识别肿瘤特异性或肿瘤相关抗原的能力，并控制了癌症（干细胞）细胞的生长，却没有意识到有无形的帮助之手。因此，免疫生物标志物在确定癌症预后和预测化疗疗效方面变得越来越重要。还有强有力的理由支持将传统抗癌疗法与免疫疗法相结合。

OncoImmunology 将接受肿瘤免疫学基础、转化和临床领域的高调投稿。欢迎提交涉及实体或血液癌症、炎症、先天和获得性免疫反应的投稿。

该刊已被国际权威数据库SCIE收录，该刊致力于发表经过严格同行评审的高质量原创文章，反映ONCOLOGYIMMUNOLOGY-IMMUNOLOGY领域的新进展、新技术、新成果，促进该领域科研交流和科研成果转化。该刊2023年影响因子为6.5，平均审稿速度为 24 Weeks ，近四年来没有被列入预警名单。如果您需要投稿发表服务及指导，可以联系我们的客服老师，我们专业专注服务期刊投稿协助10年，为您提供期刊投稿个性化定制服务，并且我们确保严格保密您的个人信息及稿件内容。